First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1.

Por Kathryn E Stephenson, Michael C Keefer, Catherine A Bunce, Doreen Frances, Peter Abbink, Lori F Maxfield, George H Neubauer, Joseph Nkolola, Lauren Peter, Christopher Lane, Harriet Park, Carl Verlinde, Angela Lombardo, Christopher Yallop, Menzo Havenga, Patricia Fast, John Treanor, Dan H Barouch
Publicado em 2018-01-01